|
40
|
116
|
6fquA |
Crystal structure of crebbp bromodomain complexd with dr09 |
|
2
|
9
|
6fo8B |
Vitamin d nuclear receptor complex 4 |
|
2
|
10
|
6fodB |
Vitamin d nuclear receptor complex 1 |
|
2
|
9
|
6fo7B |
Vitamin d nuclear receptor complex 3 |
|
29
|
124
|
6fgnA |
Solution structure of p300taz2-p63ta |
|
93
|
245
|
6ficT |
Bivalent inhibitor unc4512 bound to the taf1 bromodomain tandem |
|
30
|
130
|
6fgsA |
Solution structure of p300taz2-p73ta1 |
|
11
|
53
|
6ds6A |
Crystal structure of p300 zz domain in complex with histone h3 peptide |
|
34
|
87
|
6dnqB |
Hbz77 in complex with kix and c-myb |
|
36
|
84
|
6dmxB |
Hbz56 in complex with kix and c-myb |
|
50
|
218
|
6cw3F |
Crystal structure of a yeast saga transcriptional coactivator ada2/gcn5 hat subcomplex, crystal form 2 |
|
62
|
241
|
6cw2D |
Crystal structure of a yeast saga transcriptional coactivator ada2/gcn5 hat subcomplex, crystal form 1 |
|
80
|
274
|
6ct2A |
Myst histone acetyltransferase kat6a/b in complex with wm-1119 |
|
107
|
318
|
6bnsA |
Structure of human pregnane x receptor ligand binding domain bound tethered with src co-activator peptide and compound 25a aka bicyclic hexafluoroisopropyl 2 alcohol sulfonamides |
|
81
|
272
|
6ba4A |
Crystal structure of myst acetyltransferase domain in complex with acetyl-coa cofactor |
|
75
|
272
|
6ba2A |
Crystal structure of myst acetyltransferase domain in complex with inhibitor |
|
40
|
112
|
6axqA |
Crebbp bromodomain in complex with cpd6 (methyl 1h-indole-3-carboxylate) |
|
39
|
114
|
6alcA |
Crebbp bromodomain in complex with cpd 4 (1-(1-(cyclopropylmethyl)-3-(1h-indol-4-yl)-1,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) |
|
39
|
115
|
6ay5A |
Crebbp bromodomain in complex with cpd17 (5-(7-(difluoromethyl)-6-(1-methyl-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)-3-methylbenzo[d]thiazol-2(3h)-one) |
|
41
|
115
|
6ay3A |
Crebbp bromodomain in complex with cpd16 (5-(7-(difluoromethyl)-6-(1-methyl-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)-n-methyl-1h-indole-3-carboxamide) |
|
2
|
8
|
5yp6B |
Rorgamma (263-509) complexed with src2 and compound 6 |
|
3
|
11
|
5ycpB |
Human ppargamma ligand binding domain complexed with rosiglitazone |
|
33
|
125
|
5y7wA |
Crystal structure of the nco-a1 pas-b domain with yl-2 |
|
38
|
117
|
5xxhA |
Crystal structure analysis of the cbp |
|
168
|
621
|
5u7gA |
Crystal structure of the catalytic core of cbp |
|
39
|
114
|
5w0lA |
Crebbp bromodomain in complex with cpd10 (1-(3-(7-(difluoromethyl)-6-(1-methyl-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one) |
|
67
|
209
|
5wh1A |
Apo form of the c-terminal region of human transcription factor iib |
|
39
|
114
|
5w0eA |
Crebbp bromodomain in complex with cpd19 (3-(7-(difluoromethyl)-6-(1-methyl-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)-n-methyl-1-(tetrahydro-2h-pyran-4-yl)-1,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridine-5-carboxamide) |
|
2
|
9
|
5x8uB |
Crystal structure of the wild human ror gamma ligand binding domain. |
|
2
|
11
|
5nmbB2 |
Structure-activity relationship study of vitamin d analogs with oxolane group in their side chain |
|
2
|
10
|
5mx7B1 |
1a,20s-dihydroxyvitamin d3 vdr complex |
|
38
|
108
|
5fe0A |
Crystal structure of human pcaf bromodomain in complex with acetyllysine |
|
26
|
116
|
5b77A |
Crystal structrue of moz double phd finger in complex with histone h3 propionylation at k14 |
|
29
|
119
|
5b78A |
Crystal structure of moz double phd finger mutant-s210d/n235r in complex with histone h3 crotonylation at k14 |
|
43
|
114
|
5bt3A |
Crystal structure of ep300 bromodomain in complex with sgc-cbp30 chemical probe |
|
26
|
120
|
5b76A |
Crystal structure of moz double phd finger domain in complex with histone h3 crotonylation at k14 |
|
25
|
119
|
5b75A |
Crystal structure of moz double phd finger in complex with histone h3 butyrylation at k14 |
|
4
|
15
|
5a86C |
Structure of pregnane x receptor in complex with a sphingosine 1- phosphate receptor 1 antagonist |
|
50
|
132
|
4yymA |
Crystal structure of taf1 bd2 bromodomain bound to a butyryllysine peptide |
|
54
|
130
|
4yynA |
Crystal structure of taf1 bd2 bromodomain bound to a crotonyllysine peptide |
|
3
|
11
|
4f9mC |
Crystal structure of the ppargamma-lbd complexed with a cercosporamide derivative modulator |
|
94
|
343
|
4f3lA |
Crystal structure of the heterodimeric clock:bmal1 transcriptional activator complex |
|
4
|
10
|
4dqmB |
Revealing a marine natural product as a novel agonist for retinoic acid receptors with a unique binding mode and antitumor activity |
|
3
|
12
|
4dk7B |
Crystal structure of lxr ligand binding domain in complex with full agonist 1 |
|
1
|
8
|
4dm8C |
Crystal structure of rarb lbd in complex with 9cis retinoic acid |
|
72
|
272
|
4dncA |
Crystal structure of human mof in complex with msl1 |
|
2
|
11
|
4dmaE |
Crystal structure of era lbd in complex with ru100132 |
|
2
|
12
|
4dk8B |
Crystal structure of lxr ligand binding domain in complex with partial agonist 5 |
|
3
|
11
|
4dm6E |
Crystal structure of rarb lbd homodimer in complex with ttnpb |
|
97
|
264
|
4ci4A |
Structural basis for gl479 a dual peroxisome proliferator-activated receptor alpha agonist |
